APLM Apollomics Inc. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1944885 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 | FY2020*2020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $24.57M | $34.19M | $35.46M | $35.57M | $31.44M |
| Operating income | — | — | $976,000 | — | — |
| Interest expense | $179,000 | $150,000 | $93,000 | $83,000 | $72,000 |
| Pretax income | -$53.60M | -$172.59M | -$240.81M | -$94.80M | -$74.91M |
| Income tax | $259,000 | $10,000 | $1,000 | $1,000 | -$85,000 |
| Net income | -$53.86M | -$172.60M | -$240.81M | -$94.80M | -$74.82M |
| EPS (basic) | -52.80 | -231.99 | -844.95 | -3.37 | -0.21 |
| EPS (diluted) | -52.80 | -231.99 | -844.95 | -3.37 | -0.21 |
| Weighted avg. shares (diluted) | 1.02M | 744,000 | 285,000 | 28.11M | 361.48M |
| Balance sheet | |||||
| Cash & equivalents | $9.77M | $32.06M | $32.67M | $46.74M | $130.65M |
| Current assets | $10.27M | $39.92M | $55.79M | $99.37M | — |
| PP&E, netmay include right-of-use assets (IFRS) | $92,000 | $161,000 | $485,000 | $280,000 | — |
| Intangibles | $1.74M | $14.76M | $14.78M | $14.80M | — |
| Total assets | $13.10M | $55.39M | $76.47M | $123.44M | — |
| Current liabilities | $7.40M | $13.56M | $12.36M | $13.56M | — |
| Short-term debt | $0 | $4.24M | — | — | — |
| Total liabilities | — | — | $448.12M | — | — |
| Shareholders' equity | $4.86M | $41.23M | -$448.12M | -$212.86M | -$127.93M |
| Cash flow statement | |||||
| Operating cash flow | -$28.74M | -$43.21M | -$42.82M | -$43.31M | -$35.68M |
| Capital expenditure | $24,000 | $6,000 | $367,000 | $50,000 | $144,000 |
| Free cash flow | -$28.77M | -$43.22M | -$43.19M | -$43.36M | -$35.83M |
| Investing cash flow | $5.98M | $21.36M | $29.05M | -$38.95M | $2.33M |
| Financing cash flow | $468,000 | $21.23M | -$294,000 | -$1.64M | $125.51M |
| Stock-based compensation | $10.93M | $12.69M | $3.58M | $8.12M | $4.51M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.